[ad_1]
the vaccine anti-COVID-19 of the University of Oxford, Irbm e Astrazeneca it is well tolerated, especially in the elderly, and induces immune protection similar to that seen in young adults. This is indicated by the results of the phase 2 trial, published in the Lancet journal, carried out on 560 healthy adults, of whom 240 are over 70 years old.
Covid vaccine, drive-ins in the prophylaxis plan: government divided into obligations
Covid vaccine, Pfizer ad: “95% effective.” Tested on 43,500 people without problems. WHO: second wave fought without treatment
Covid vaccine, what we know and when it will be available: 12 companies have already reached phase 3
To find out if the vaccine protects against SarsCov2 infection, we will have to wait for the results of phase 3 of the ongoing trial. Of the vaccine, of which the European Medicines Agency (EMA) launched continuous review in early October, the first step in the approval process, some phase 3 results had been anticipated in the unscientific press.
Therefore, this vaccine shows “similar safety and immunogenicity results in healthy people 56 years of age and older and in adults 18 to 55 years of age.” The test indicates that the product “causes few side effects” and activates responses related to “both forms of immunity”, cellular and antibody, “In all age groups and in low and standard doses”. In particular, “a T-cell response within 14 days of the first dose and an antibody response within 28 days of the booster dose” was observed. Phase 3 studies are currently underway to confirm these findings, as well as the efficacy of the vaccine to protect against Sars-CoV-2 infection in a larger sample of people. including older people with pre-existing conditions».
Vaccine-induced immune responses are typically lower in the elderly because the immune system gradually deteriorates with age, making the elderly even more susceptible to infections, says Andrew Pollard of the University of Oxford, lead author of the study. for this it is essential that anti-Covid vaccines are tested in this group, which is also a priority group for immunization. “The robust cellular and antibody responses observed in older people in our study are encouraging – says Maheshi Ramasamy from the British university, a co-author of the trial – Populations most at risk of developing severe Covid-19 include people with health problems. Adults older and pre-existing “. Therefore, in light of the results recorded, “we hope that our vaccine will help protect” from the new coronavirus “some of the most vulnerable sectors of society, but more research will be needed before we are sure.”
Last update: 12:23
© REPRODUCTION RESERVED
[ad_2]
